Related Experiment Video

Updated: Jun 28, 2026

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison

Oren Pasvolsky1, Curtis Marcoux2, Denái R Milton3

  • 1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Leukemia & Lymphoma
|June 26, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Related Experiment Videos

Last Updated: Jun 28, 2026

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Articles linked to this work by shared authors, journal, and citation graph.

From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".

Haematologica·2026

Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200.

Blood advances·2026

Activating RARβ to overcome immunomodulatory drug resistance in t(4;14) human myeloma.

Leukemia·2026

Oral Nicotine Pouches and the Emerging Addiction Crisis Among Youth in Pakistan: A Perspective.

Health science reports·2026

Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.

British journal of haematology·2026

Factors Associated With Overall Survival and 90-Day Mortality Following Resection of Melanoma Brain Metastases.

Operative neurosurgery (Hagerstown, Md.)·2026

Evaluation of hypomethylating agents with or without venetoclax in patients with accelerated phase and blast phase myeloproliferative neoplasms: a HERO consortium study.

Leukemia & lymphoma·2026

Soluble PD-L1 as prognostic biomarker in acute myeloid leukemia.

Leukemia & lymphoma·2026

Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia.

Leukemia & lymphoma·2026

Impact of Area Deprivation Index in patients with newly diagnosed acute myeloid leukemia treated with a venetoclax-based regimen: a single-center retrospective study.

Leukemia & lymphoma·2026

Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies.

Leukemia & lymphoma·2026

How to treat hepatic extra-medullary involvement of myeloma: a case report and review of literature.

Leukemia & lymphoma·2026

Linear IgA Bullous Dermatosis: A Rare Immune-Related Cutaneous Adverse Event Due to Pembrolizumab.

Cureus·2026

Short-Term Intensive Insulin Therapy as a Remission Induction Strategy in Newly Diagnosed Type 2 Diabetes Mellitus: A Systematic Review.

Cureus·2026

Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors.

ChemMedChem·2026

Invariant chain controls HLA-DQ folding and shapes the HLA class II proxiome.

Journal of immunology (Baltimore, Md. : 1950)·2026

Ultrasound-responsive PLGA nanoparticles co-loaded with celecoxib and catalase enhance the therapeutic efficacy of imatinib in gastrointestinal stromal tumors.

International journal of pharmaceutics·2026

Machine Learning-Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma.

JHEP reports : innovation in hepatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us